news

M&A attorney Aravind Venugopal has rejoined Indian law firm Khaitan & Co as a partner in Bengaluru after a year-long stint as general counsel at online insurance company Acko.

Venugopal previously joined Khaitan in 2013 and made partner in 2019, before moving to head the legal team at Acko in 2022. He specialises in M&A and contentious exits.

During his earlier stint at Khaitan, Venugopal advised Nippon Life Insurance Company on its share acquisition in Reliance Nippon Life Mutual Funds, Siemens AG on the carve-out of its Indian gas and power business, and Axis Bank on its $1 billion acquisition of Citibank’s retail banking business, one of the largest in the Indian banking sector.

Venugopal’s hire is part of Khaitan’s planned expansion of its corporate offerings in Southern India. In April, the firm hired corporate attorneys Promode Murugavelu and Rakki Partani as partners in Chennai and Bengaluru, respectively.

Khaitan also hired corporate partner Radhika Iyer in Mumbai in June.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Latham, Milbank, SyCip act on largest greenfield infra FDI deal in Philippines

by Nimitt Dixit |

Milbank and SyCip Salazar Hernandez & Gatmaitan have acted for global investor Actis on its strategic partnership with the Philippines’ Meralco and its subsidiary, Solar Philippines New Energy Corporation, advised by Latham & Watkins, to invest $600 million in the Terra Solar Project.

Malaysia: A&O guides IHH’s $900 mln acquisition of Island Hospital

by Nimitt Dixit |

A&O Shearman is advising IHH Healthcare, an operator of private hospitals in Asia, on its $900 million acquisition of Island Hospital in Penang from Affinity Equity Partners.

Trilegal, Latham, Quillon act on Platinum Equity’s India PE debut

by Nimitt Dixit |

Trilegal and Latham & Watkins have advised U.S.-based buyout fund Platinum Equity on its debut private equity deal in India, in the form of the acquisition of a majority stake in Inventia Healthcare, a Mumbai-based pharmaceutical company, at a valuation of $300 million.